Media Media Kit MEDIA KIT The Quotient media kit is designed to help journalists research our company for background information or follow-up stories. Please contact us if you need more detailed information or to schedule interviews. Approved imagery Browse through our approved corporate photos. These images may be used for editorial purposes as long as the connection to Quotient is clearly recognizable. Commercial use is prohibited. IMAGE CAPTION SIZE DOWNLOAD Hand, close-up of microarray 2.1 MB JPG MosaiQ by Quotient instrument and lab technician 2.5 MB JPG MosaiQ by Quotient instrument and microarray cartridge loading dock 2.3 MB JPG Lab technicians blood sample, lab 2.5 MB JPG MosaiQ COVID-19 Antibody Microarray 6.0 MB MP4 MosaiQ COVID-19 Antibody Microarray Infographic 0.2 MB PDF Approved company descriptions Short Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. Quotient has two key product portfolios, Alba by Quotient, quality blood bank reagents used in laboratories around the world, and MosaiQ™ by Quotient, the world’s first fully automated, consolidated testing platform. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. MosaiQ by Quotient has been recognized with a Red Dot Product Design Award. Long Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multimodal, multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration. The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. In April 2021, the full MosaiQ by Quotient system has been recognized with a Red Dot Product Design Award. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. Meet our management team We have over 30 years’ experience manufacturing and supplying conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market. We are developing MosaiQ by Quotient, our proprietary technology platform, to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes. Manuel O. Méndez, Chief Executive Officer Ali Kiboro, Chief Financial Officer Christian Albrich, Chief People Officer Mohammad El Khoury, Chief Commercial Officer Dr. Christine Ginocchio, Chief Scientific & Medical Officer Dr. Michael Hausmann, Chief Technology Officer Office locations EYSINS Switzerland EDINBURGH Scotland Global (HQ) Quotient Suisse SA B1, Business Park Terre Bonne Route de Crassier 13 Eysins, 1262 Switzerland UK Quotient 5 James Hamilton Way Milton Bridge Penicuik EH26 0BF United Kingdom USA Quotient 301 S State St Newtown, PA 18940-1997 United States Social We are proud to be active and responsive on Twitter and LinkedIn. Follow us to stay updated on Quotient news, announcements & updates. Twitter @QuotientHQ LinkedIn QuotientLtd Latest social posts 17 NOV 2021 Up to 132 spots can be printed on the MosaiQ Microarray. Learn more about what we mean by spots: 🔗 https://t.co/qyWSz6TFPv #labinnovation https://t.co/mTe9rJG9xp 16 NOV 2021 Quotient Limited Provides Second Quarter Fiscal 2022 Results. Read the full press release: 🔗 https://t.co/uRj2FNgwIL https://t.co/6gX2IWuYCU MENU QUICK ACTIONS Linkedin Twitter Vimeo THE FUTURE, MADE POSSIBLE. © Copyright 2021, All Rights Reserved. PRIVACY POLICY LEGAL NOTICE We use cookies on this site to enhance your user experience By clicking the Accept and Proceed button, you agree to our privacy policy. ACCEPT AND PROCEED